Navigation Links
MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
Date:3/9/2009

obtain an immediate supply of insulin and the ability to supply our insulin needs for the future, even if we are unable to acquire the facility itself. We are pleased with this opportunity to secure our insulin supply, which brings AFRESA one step closer to commercial readiness."

Additional information about this transaction is available in a Current Report on Form 8-K filed by MannKind with the Securities and Exchange Commission earlier today.

About AFRESA(R)

AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The pharmacokinetic profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscri
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
2. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
5. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
6. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
7. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
8. MannKind to Present at the UBS Global Life Sciences Conference
9. MannKind Corporation Reports Second Quarter Financial Results
10. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
11. MannKind to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Mass. , Aug. 31, 2015  RXi ... company focused on discovering and developing innovative therapies ... today announced that the 30-day review period following ... (IND) for ocular indications with the U.S. Food ... IND is now active. Logo ...
(Date:8/31/2015)... and SHANGHAI , ... privately-held biopharmaceutical company developing next-generation antibiotics, today announced ... clinical study for its lead drug candidate MRX-I. ... treat drug-resistant bacteria such as MRSA and VRE, ... better tolerated therapeutic option than currently available oxazolidinone ...
(Date:8/31/2015)... , Aug. 31, 2015 LabStyle ... Diabetes Management Solution, today announced it recently closed ... Funds will be used to support the global ... Dario, a mobile, cloud-based, diabetes management solution that ... ,all-in-one, pocket-sized, blood glucose monitoring device, and for ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory ... in the drug development approval process. Thus, innovator companies must understand what will ... Inc., a Chicago-based CMO, has been hosting multiple educational panels and seminars for ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... SEATTLE, Nov. 20 Scientists have announced,that they ... opening the possibility of patient-specific medical treatments and,research ... Wesley J. Smith, the Discovery Institute,s Senior Fellow ... Brave New World, hailed the,breakthrough as demonstrating that ...
... - ARIUS Research Inc., (TSX:,ARI), a biotechnology ... of,antibody therapeutics, today announced that Daniel S. ... at the 14th Annual BioNorth,Biotechnology and Life ... non-traditional approach to drug discovery using its ...
... 20 - Third quarter Consolidated Net Income ... Third Quarter 2006 Results Adversely Affected by,Northern Hostilities ... Issue of,Debentures Primarily for the Financing of the Strategic ... and Poor,s Affiliation Oil Refineries Ltd. (TASE: ORL) ...
Cached Biology Technology:ARIUS to present at BioNorth Biotechnology and Life Sciences Conference 2Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 2Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 3Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 4Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 5Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 6Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 7Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 8Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 9Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 10Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 11
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/10/2015)... August 10, 2015 The latest 364 ... comprehensive analysis of the global border security market . ... of $16.4bn in 2015. Now: Border security is ... example of the business critical issue you need to know ... visiongain ,s objective analysis of how this will impact your ...
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Humans spend greater than 90 percent of their time ... scientists estimate, make up half of the world,s biomasssome ... most often meet them within enclosed spaces. So, that,s ... new report issued by the National Institute of Standards ...
... new method for rapidly solving the three-dimensional structures of ... proteins, may speed drug discovery by providing scientists with ... published May 20 in Nature Methods . ... for Biological Studies, provides a shortcut for determining the ...
... of the small adrenal tumors that cause big problems with ... to retain too much sodium, researchers report. The study ... a mutation of the gene KCNJ5 is twice as likely ... as it points to potential new treatments for some patients ...
Cached Biology News:Report details efforts to improve, advance indoor microbial sampling 2Speeding up drug discovery with rapid 3-D mapping of proteins 2Speeding up drug discovery with rapid 3-D mapping of proteins 3Common genetic mutation increases sodium retention, blood pressure 2Common genetic mutation increases sodium retention, blood pressure 3
Shake 'n' Stack oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual)...
... Cell Expansion Kit - Monolayer Plus is a ... expansion as a monolayer in a serum-free environment. ... Media Supplement, which has been optimized for neural ... . (1996) Genes & Development 10 :3129). ...
... thymus Description: Topoisomerase I relaxes both ... breakage and rejoining of phosphodiester bonds (1,2) . ... to be differentiated by a single nucleotide pair ... active in the absence of Mn 2+ ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
Biology Products: